Disease · EFO_1000235

Endometrial Intraepithelial Neoplasia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Endometrial Intraepithelial Neoplasia. Diseases, record EFO_1000235. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1000235

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Endometrial Intraepithelial Neoplasia; Open Targets
Open Targets ID: EFO_1000235; Open Targets
NCI Thesaurus: C27789; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 5 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEGESTROL ACETATE	CHEMBL1201139	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TIRZEPATIDE	CHEMBL4297839	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
EXEMESTANE	CHEMBL1200374	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVONORGESTREL	CHEMBL1389	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
METFORMIN HYDROCHLORIDE	CHEMBL1703	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets55

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PGR	Progesterone receptor	2	Progesterone receptor agonist	Phase 2	https://conductscience.org/library/genes/5241	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4697	Drugs and targets
COXFA4L2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/56901	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1588	Drugs and targets
GIPR	Gastric inhibitory polypeptide receptor	1	Gastric inhibitory polypeptide receptor agonist	Phase 2	https://conductscience.org/library/genes/2696	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	1	Glucagon-like peptide 1 receptor agonist	Phase 2	https://conductscience.org/library/genes/2740	Drugs and targets
GPD2	Glycerol-3-phosphate dehydrogenase, mitochondrial	1	Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor	Phase 2	https://conductscience.org/library/genes/2820	Drugs and targets
MT-ND1	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4535	Drugs and targets
MT-ND2	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4536	Drugs and targets
MT-ND3	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Phase 2	https://conductscience.org/library/genes/4537	Drugs and targets

1 to 10 of 55

See all 55 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03300557	Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer	Phase 2	40	2025-06-03	Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma	EXEMESTANE	Its record names the disease	ClinicalTrials.gov
NCT00503581	Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia	Phase 2	9	2020-10-14	High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer	MEGESTROL ACETATE	Its record names the disease	ClinicalTrials.gov
NCT07349641	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer	Phase 2	55		Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma	LEVONORGESTREL, TIRZEPATIDE	Its record names the disease	ClinicalTrials.gov
NCT04576104	Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer	Phase 2	51		Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma	MEGESTROL ACETATE, METFORMIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT07605247	Tirzepatide in the Treatment of Endometrial Cancer	Phase 2	30		Endometrial Cancer	TIRZEPATIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1000235

GET https://conductscience.org/api/diseases/v1/EFO_1000235/targets?page=2

API reference For AI assistants